stockrowExelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) Return on assets
Exelixis, Inc.'s return on assets over the twelve months to 30 September 2026 was 33.2%, up 6.2 percentage points from fiscal 2025 (27.0%). Over the past ten years it has ranged from −49.3% (fiscal 2015) to 66.4% (fiscal 2018); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 27.0% | 9.32 |
| FY2024 | 17.7% | 10.79 |
| FY2023 | 6.91% | 0.50 |
| FY2022 | 6.41% | (3.31) |
| FY2021 | 9.72% | 4.16 |
| FY2020 | 5.56% | (13.85) |
| FY2019 | 19.4% | (47.02) |
| FY2018 | 66.4% | 41.77 |
| FY2017 | 24.7% | 39.79 |
| FY2016 | −15.1% | 34.21 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ASND Ascendis Pharma A/S compare | 44.3% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 41.3% |
| EXEL Exelixis, Inc. | 33.2% |
| HALO Halozyme Therapeutics, Inc. compare | 17.1% |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.76% |
| BNTX BioNTech SE Sponsored ADR compare | −7.22% |
| INSM Insmed, Inc. compare | −26.4% |
| BBIO BridgeBio Pharma, Inc. compare | −37.5% |
| SMMT Summit Therapeutics PLC compare | −159.1% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on EXEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement